## (19) World Intellectual Property **Organization**

International Bureau



# 

## (43) International Publication Date 19 May 2005 (19.05.2005)

## PCT

## (10) International Publication Number WO 2005/044197 A2

(51) International Patent Classification<sup>7</sup>:

**A61K** 

(21) International Application Number:

PCT/US2004/036551

(22) International Filing Date:

1 November 2004 (01.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/516,838

4 November 2003 (04.11.2003) US 30 March 2004 (30.03.2004) US

60/557,631 60/598,215

2 August 2004 (02.08.2004) US


- (71) Applicant (for all designated States except US): OPTI-MER PHARMACEUTICALS, INC. [US/US]; 10110 Sorrento Valley Road, Suite C, San Diego, CA 92121 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DUFFIELD, Jonathan [GB/US]; 3865 Albatross Street, San Diego,


CA 92103 (US). MARBY, Kenneth [US/US]; 3511 Sixth Avenue, Apt.2D, San Diego, CA 92103 (US). O'HARE, Sean [US/US]; 2376E Altisma Way, Carlsbad, CA 92009 (US). HWANG, Chan-Kou [US/US]; 11402 Ocean Ridge Way, San Diego, CA 92130 (US). ICHIKAWA, Yoshitaka [JP/US]; 4848 Algonquin Court, San Diego, CA 92130

- (74) Agent: PEREIRA, Laura, Esq.; Catalyst Law Group, APC, 4330 La Jolla Village Drive,, Suite 220, San Diego, CA 92122 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

### (54) Title: SYNTHESIS OF GLYCOPEPTIDES WITH SUPERIOR PHARMACOKINETIC PROPERTIES





Gb-8-13-Gc-8-13-Gc-8-13-Gc

(57) Abstract: The present invention relates to novel glycopeptides having improved pharmacokinetic properties, improved stability, methods of preparing said novel glycopeptides, and methods to use said novel glycopeptides.

#### 

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only

- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only

#### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.